EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 745 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR FDA Approves Oral Combination of Decitabine and Cedazuridine Tablets with Venetoclax... June 3, 2026 The Power of Fruits and Vegetables December 18, 2020 FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced... May 26, 2025 Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in... June 8, 2026 Load more HOT NEWS 105-Year-Old Woman Sets Record For 100-Meter Dash Study Finds Possible New Treatment for Metastatic Breast Cancer That Has... Can Eating Grilled or Charred Foods Cause Cancer? Pembrolizumab Concurrent with Radiotherapy Does Not Improve the Tumour Control and...
